tyramine has been researched along with Tachycardia in 10 studies
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
Excerpt | Relevance | Reference |
---|---|---|
" Norepinephrine was elevated in p75-/- atria, but stimulating norepinephrine release with tyramine produced less tachycardia in p75-/- mice than wild type mice." | 3.74 | Regulation of cardiac innervation and function via the p75 neurotrophin receptor. ( Bilimoria, P; Birren, SJ; Gritman, K; Habecker, BA; Linick, C; Lorentz, CU; Woodward, W, 2008) |
"We measured norepinephrine spillover (the rate of entry of norepinephrine into the venous circulation) in the arms and legs both before and in response to exposure to three stimuli (the cold pressor test, sodium nitroprusside infusion, and tyramine infusion) in 10 patients with the postural tachycardia syndrome and in 8 age- and sex-matched normal subjects." | 3.70 | The neuropathic postural tachycardia syndrome. ( Biaggioni, I; Black, B; Costa, F; Ertl, A; Jacob, G; Robertson, D; Robertson, RM; Shannon, JR; Stein, M; Wathen, M, 2000) |
"The tachycardia was abolished by treatment with the beta-antagonist propranolol, demonstrating that it was mediated by catecholamines acting on cardiac beta-receptors." | 1.31 | Animal model of neuropathic tachycardia syndrome. ( Appalsamy, M; Carson, RP; Davis, TL; Diedrich, A; Robertson, D, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
JAMES, TN | 1 |
NADEAU, RA | 1 |
Ovchinnikov, V | 1 |
Suzuki, G | 1 |
Canty, JM | 1 |
Fallavollita, JA | 1 |
Habecker, BA | 1 |
Bilimoria, P | 1 |
Linick, C | 1 |
Gritman, K | 1 |
Lorentz, CU | 1 |
Woodward, W | 1 |
Birren, SJ | 1 |
Jacob, G | 1 |
Costa, F | 1 |
Shannon, JR | 1 |
Robertson, RM | 1 |
Wathen, M | 1 |
Stein, M | 1 |
Biaggioni, I | 1 |
Ertl, A | 1 |
Black, B | 1 |
Robertson, D | 2 |
Carson, RP | 1 |
Appalsamy, M | 1 |
Diedrich, A | 1 |
Davis, TL | 1 |
Brisse, B | 1 |
Bender, F | 1 |
Lohmann, FW | 1 |
Schüren, KP | 1 |
Vigliani, EC | 1 |
Cavagna, G | 1 |
Locati, G | 1 |
Foa, V | 1 |
Varagić, VM | 1 |
Kazić, T | 1 |
Wildenthal, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2011-08-15 | Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.) | ||
Muscular and Cutaneous Dysfunction in Postural Tachycardia Syndrome[NCT04170725] | 15 participants (Actual) | Interventional | 2020-01-10 | Active, not recruiting | |||
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND GASTROINTESTINAL SYMPTOMS: Contribution of Gastrointestinal Peptides[NCT03263819] | 25 participants (Actual) | Observational | 2017-06-20 | Completed | |||
Mechanism of Glucose-dependent Insulinotropic Polypeptide (GIP) on Splanchnic Venous Capacitance in Postural Tachycardia Syndrome[NCT05375968] | 50 participants (Anticipated) | Interventional | 2023-02-25 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention
Intervention | () |
---|---|
Atenolol | 0 |
Placebos | 0 |
Droxidopa | 0 |
10 other studies available for tyramine and Tachycardia
Article | Year |
---|---|
THE CHRONOTROPIC ACTION OF TYRAMINE STUDIED BY DIRECT PERFUSION OF THE SINUS NODE THROUGH ITS ARTERY.
Topics: Arteries; Coronary Vessels; Dogs; Injections, Intra-Arterial; Perfusion; Pharmacology; Research; Res | 1964 |
Blunted functional responses to pre- and postjunctional sympathetic stimulation in hibernating myocardium.
Topics: Animals; Heart; Myocardial Contraction; Myocardial Stunning; Stellate Ganglion; Swine; Sympathetic N | 2005 |
Regulation of cardiac innervation and function via the p75 neurotrophin receptor.
Topics: Adrenergic Uptake Inhibitors; Aging; Animals; Cell Differentiation; Growth Cones; Heart; Heart Atria | 2008 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
The neuropathic postural tachycardia syndrome.
Topics: Adult; Arm; Autonomic Nervous System Diseases; Blood Pressure; Case-Control Studies; Cold Temperatur | 2000 |
Animal model of neuropathic tachycardia syndrome.
Topics: Adrenergic Agents; Animals; Autonomic Nervous System Diseases; Blood Pressure; Disease Models, Anima | 2001 |
[Experimental findings on tyramine-dependent release of noradrenaline in various parts of the heart under the influence of practolol].
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Heart; Heart Atria; Heart Ventricles; | 1975 |
[Current status of diagnostics in pheochromocytoma].
Topics: Abdomen; Adrenal Gland Neoplasms; Adult; Anxiety; Catecholamines; Diagnosis; Diagnostic Errors; Epin | 1972 |
Biological effects of nitroglycol on the metabolism of catecholamines. Clinical and experimental observations.
Topics: Adult; Amphetamine; Animals; Catecholamines; Death, Sudden; Environmental Exposure; Epinephrine; Fla | 1968 |
The acute effect of 6-hydroxy-dopamine on the blood pressure responses to eserine and tyramine in the rat.
Topics: Animals; Blood Pressure; Drug Antagonism; Female; Male; Nerve Endings; Norepinephrine; Phenethylamin | 1970 |
Responses to cardioactive drugs of fetal mouse hearts maintained in organ culture.
Topics: Acetylcholine; Animals; Arrhythmias, Cardiac; Bradycardia; Culture Techniques; Digitalis Glycosides; | 1971 |